Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Status:
Terminated
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a
single dose of azithromycin for prevention of progression of COVID-19 in patients with a
recent positive SARS-CoV-2 test who are not currently hospitalized.
Phase:
Phase 3
Details
Lead Sponsor:
Thomas M. Lietman University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Pfizer Stanford University